CytomX Therapeutics, Inc. 4

Reporting person Charles S. Fuchs was granted a stock option for 118,000 shares of CytomX Therapeutics, Inc. common stock at a $3.24 exercise price as equity compensation.

On July 24, 2026, Charles S. Fuchs received a stock option grant from CytomX Therapeutics, Inc. for 118,000 shares of common stock at an exercise price of $3.24 per share, with vesting occurring in equal monthly installments over three years beginning July 24, 2026, and an expiration date of July 23, 2036. This award appears to be a routine equity compensation grant rather than an open-market purchase or sale, and it increased his derivative exposure to the company by the full 118,000 shares, corresponding to a notional value of approximately $382,320 at the stated exercise price. The option vests 1/36th per month, contingent on his continued service, and represents his entire reported derivative holding in this filing, with no other concurrent purchases or sales of common stock disclosed.

Filing Facts

CIK

1501989

Ticker

CTMX

Form

4

Source Type

fda

Accession

0001610717-26-000345

Alert Tier

5